FDA final guidance addresses prescription-drug companion apps and labeling
FDA’s October 20 announcement describes recommendations on drug-company companion software, prescribing-information references and submissions to the agency.
What the record says
FDA released final guidance on October 20, 2026 addressing apps distributed by drug companies alongside prescription medicines. Its announcement says the guidance covers when app content is considered required labeling or promotional labeling, when software should be referenced in prescribing information, and what companies should submit to FDA. FDA distinguishes software connected to medical devices from standalone tools such as symptom trackers and dose reminders. For standalone apps, the announcement describes prescribing-label references where a company can show essential use for safety and effectiveness or a meaningful clinical benefit. FDA says most user-facing companion-app content will be treated as promotional material.
Source details and supporting locations.
Practical next step
Drug companies and technology partners should read the complete guidance when assessing a particular product and its labeling.
Limits and what is not established
This announcement does not approve a specific app, establish clinical benefit for every companion tool or mean that every health app falls within this guidance.
Sources checked October 22, 2026. Later notices may change instructions or arrangements.
Original sources
U.S. Food and Drug Administration: original information